On this page of StockholderLetter.com we present the latest annual shareholder letter from Medpace Holdings, Inc. — ticker symbol MEDP. Reading current and past MEDP letters to shareholders can bring important insights into the investment thesis.

August J. Troendle Chief Executive Officer and Chairman of the Board of Directors Jesse J. Geiger President Susan E. Burwig Executive Vice President, Operations Stephen P. Ewald General Counsel and Corporate Secretary Kevin M. Brady Chief Financial Officer and Treasurer August J. Troendle Chairman of the Board of Directors Brian T. Carley Audit Committee, Chair Nominating and Governance Committee Fred B. Davenport Jr. Lead Director Compensation Committee, Chair Audit Committee Nominating and Governance Committee Femida H. Gwadry-Sridhar Nominating and Governance Committee Ashley M. Keating Nominating and Governance Committee Robert O. Kraft Audit and Compensation Committees Nominating and Governance Committee Cornelius P. "Neal" McCarthy III Compensation Committee Nominating and Governance Committee Medpace Holdings, Inc. 5375 Medpace Way Cincinnati, Ohio 45227 513-579-9911 www.medpace.com Equiniti Trust Company, LLC 718-921-8124 Email: HelpAST@equiniti.com equiniti.com/us/ast-access Lauren Morris 513-579-9911, ext. 11994 l.morris@medpace.com Deloitte & Touche LLP 50 W 5th St. Suite 200 Cincinnati, Ohio 45202 Julie Hopkins 513-579-9911, ext. 12627 j.hopkins@medpace.com NASDAQ under ticker symbol MEDP The information included in this Annual Report on Form 10-K as filed with the U.S. Securities and Exchange Commission on February 13, 2024 presents information as of and for the fiscal year ended December 31, 2023 and, accordingly, does not include information for updates or developments that are not required to be otherwise reported in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
 • shareholder letter icon 4/3/2024 Letter Continued (Full PDF)
 • stockholder letter icon 4/5/2023 MEDP Stockholder Letter
 • stockholder letter icon More "Biotechnology" Category Stockholder Letters
 • Benford's Law Stocks icon MEDP Benford's Law Stock Score = 94


MEDP Shareholder/Stockholder Letter Transcript:


August J. Troendle
Chief Executive Officer and
Chairman of the Board of Directors
Jesse J. Geiger
President
Susan E. Burwig
Executive Vice President, Operations
Stephen P. Ewald
General Counsel and Corporate Secretary
Kevin M. Brady
Chief Financial Officer and Treasurer
August J. Troendle
Chairman of the Board of Directors
Brian T. Carley
Audit Committee, Chair
Nominating and Governance Committee
Fred B. Davenport Jr.
Lead Director
Compensation Committee, Chair
Audit Committee
Nominating and Governance Committee
Femida H. Gwadry-Sridhar
Nominating and Governance Committee
Ashley M. Keating
Nominating and Governance Committee
Robert O. Kraft
Audit and Compensation Committees
Nominating and Governance Committee
Cornelius P. "Neal" McCarthy III
Compensation Committee
Nominating and Governance Committee
Medpace Holdings, Inc.
5375 Medpace Way
Cincinnati, Ohio 45227
513-579-9911
www.medpace.com
Equiniti Trust Company, LLC
718-921-8124
Email: HelpAST@equiniti.com
equiniti.com/us/ast-access
Lauren Morris
513-579-9911, ext. 11994
l.morris@medpace.com
Deloitte & Touche LLP
50 W 5th St.
Suite 200
Cincinnati, Ohio 45202
Julie Hopkins
513-579-9911, ext. 12627
j.hopkins@medpace.com
NASDAQ under ticker
symbol MEDP
The information included in this Annual Report on Form 10-K as filed with the U.S. Securities and Exchange
Commission on February 13, 2024 presents information as of and for the fiscal year ended December 31, 2023 and,
accordingly, does not include information for updates or developments that are not required to be otherwise reported
in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023.



shareholder letter icon 4/3/2024 Letter Continued (Full PDF)
 

MEDP Stockholder/Shareholder Letter (Medpace Holdings, Inc.) | www.StockholderLetter.com
Copyright © 2023 - 2025, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.